Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 15, 2014

Primary Completion Date

June 1, 2015

Study Completion Date

June 1, 2015

Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

Serum-Derived Bovine Immunoglobulin

Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)

OTHER

Placebo

"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.~Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."

Trial Locations (1)

06106

Connecticut Childrens Medical Center, Farmington

All Listed Sponsors
lead

Connecticut Children's Medical Center

OTHER

NCT02358694 - Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS | Biotech Hunter | Biotech Hunter